Inventor · disambiguated record
Robert Babb
Also filed as: BABB II ROBERT G · BABB ROBERT
25 granted patents·21 pending applications·401 citations·filing 2006–2025
95Inventor score
Top patents by PatentIndex Score
46 records- 0197US10975139B1Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Apr 13, 2021·15 cites·20 claims
- 0297US10954289B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Mar 23, 2021·28 cites·28 claims
- 0397US10787501B1Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2020·Granted Sep 29, 2020·224 cites·20 claims
- 0497US7771997B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2008·Granted Aug 10, 2010·55 cites·8 claims
- 0595US8389239B2Enhanced expression and stability regionsCHEN GANG·Filed 2010·Granted Mar 5, 2013·17 cites·20 claims
- 0693US11808766B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2020·Granted Nov 7, 2023·2 cites·47 claims
- 0793US11732030B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2021·Granted Aug 22, 2023·2 cites·51 claims
- 0893US11142578B2Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereofREGENERON PHARMA·Filed 2017·Granted Oct 12, 2021·6 cites·26 claims
- 0992US10752698B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2015·Granted Aug 25, 2020·5 cites·26 claims
- 1091US11787867B2Anti-GITR antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Oct 17, 2023·2 cites·24 claims
- 1189US9222106B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2013·Granted Dec 29, 2015·4 cites·32 claims
- 1289US2025340672A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1388US12480947B2Method for generating high affinity antibodiesREGENERON PHARMA·Filed 2023·Granted Nov 25, 2025·0 cites·20 claims
- 1486US12251440B2Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsREGENERON PHARMA·Filed 2023·Granted Mar 18, 2025·0 cites·16 claims
- 1586US7904892B2Systems and methods for identifying and displaying dependenciesNORTHROP GRUMMAN CORP·Filed 2006·Granted Mar 8, 2011·38 cites·30 claims
- 1686US2024124613A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1785US11530277B2Compositions and methods for making antibodies based on use of an expression-enhancing locusREGENERON PHARMA·Filed 2017·Granted Dec 20, 2022·2 cites·41 claims
- 1882US2024156070A1Common light chain mouseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1980US9562238B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2015·Granted Feb 7, 2017·1 cites·35 claims
- 2077US12331127B2Therapeutic uses of anti-GITR antibodiesREGENERON PHARMA·Filed 2023·Granted Jun 17, 2025·0 cites·55 claims
- 2177US2025014675A1Off-target prediction method for antigen-recognition molecules binding to mhc-peptide targetsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2276US12503520B2Compositions and methods for making antibodies based on use of an expression-enhancing locusREGENERON PHARMA·Filed 2022·Granted Dec 23, 2025·0 cites·20 claims
- 2376US2025313624A1Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the sameREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2476US2025250342A2Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2572US2020377618A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2671US12371487B2Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the sameREGENERON PHARMA·Filed 2021·Granted Jul 29, 2025·0 cites·39 claims
- 2771US10415055B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2018·Granted Sep 17, 2019·0 cites·26 claims
- 2870US10787522B2VL antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·0 cites·20 claims
- 2968US9932605B2Enhanced expression and stability regionsREGENERON PHARMA·Filed 2016·Granted Apr 3, 2018·0 cites·21 claims
- 3067US2019090462A1Common light chain mouseREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 3167US2019021295A1Common light chain mouseREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 3266US2024158515A1Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3366US2023338477A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3465US2024173426A1Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3563US2021355238A1Non-human animals that select for light chain variable regions that bind antigenREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3662US2012192300A1Common Light Chain MouseBABB ROBERT·Filed 2012·Application pending·0 cites
- 3762US2023416396A1Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3862US2024052051A1Anti-tfr:payload fusions and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3960US11512144B2Compositions and methods for making antibodies based on use of an expression-enhancing lociREGENERON PHARMA·Filed 2017·Granted Nov 29, 2022·0 cites·43 claims
- 4059US2015266976A1Vl antigen binding proteins exhibiting distinct binding characteristicsREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 4159US2013185821A1Common Light Chain MouseREGENERON PHARMA·Filed 2013·Application pending·0 cites
- 4257US2013045492A1Methods For Making Fully Human Bispecific Antibodies Using A Common Light ChainREGENERON PHARMA·Filed 2012·Application pending·0 cites
- 4354US12466870B2NY-ESO-1 T cell receptors and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Nov 11, 2025·0 cites·32 claims
- 4452US11111314B2Non-human animals that select for light chain variable regions that bind antigenREGENERON PHARMA·Filed 2016·Granted Sep 7, 2021·0 cites·25 claims
- 4550US2022330532A1Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4650US2018355038A1Optimized Anti-CD3 Bispecific Antibodies and Uses ThereofREGENERON PHARMA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Babb files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →